JILIN, China, Feb. 15 /PRNewswire-FirstCall/ -- Global Pharmatech, Inc. , China-based developer and manufacturer of proprietary drugs, announced today that it has retained The Anne McBride Company, Inc. (AMcB, http://www.annemcbride.com/), a full service financial communications and strategic consulting firm headquartered in New York, to provide strategic investor relations and financial communications counsel.
Ms. Lianqin Qu, Chairman of Global Pharmatech, Inc. commented, “Our partnership with The Anne McBride Company will assist in the implementation of our strategic growth and communications plan as we broaden our relationships with U.S. investment firms. We are particularly pleased with AMcB’s impressive track record of enhancing shareholder value for foreign small-cap clients. The Company is well respected on Wall Street and has vast experience in the finance industry, which provides us with confidence that they can meet our expectations. We are convinced the firm’s expertise will prove invaluable going forward.”
“We are excited to work with Global Pharmatech especially at this early stage of its entry into the U.S. capital markets,” stated Anne McBride, Chairman and CEO of The Anne McBride Company. “Having worked closely with many successful small-cap firms in China, we are confident that we will be able to broaden the Company’s communications strategy and help facilitate the expansion of the Company’s current shareholder base.”
About Global Pharmatech
Natural Pharmatech, through its subsidiaries, develops, manufactures and markets proprietary drugs that are based on Traditional Chinese Medicine while utilizing modern facilities and advanced R&D technologies. Natural Pharmatech offers a full range of “start to finish” biotech services, from R&D and testing, to manufacturing drugs in liquid and solid dose forms, to sales and marketing. Natural Pharmatech utilizes unique extraction methods and innovative techniques that have been developed by its R&D team. Natural Pharmatech’s core business to date has been licensing its R&D patents and technologies for botanical/biological drug products. Natural Pharmatech’s operations are currently based in the People’s Republic of China with sales distribution in China, Singapore and Indonesia.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This news release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-KSB, recent and forthcoming Quarterly Reports on Form 10-QSB, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.
Contact: Brandi Piacente Investor Relations The Anne McBride Co. 212-983-1702 x208 Email: bpiacente@annemcbride.com
Global Pharmatech, Inc.
CONTACT: Brandi Piacente, Investor Relations, The Anne McBride Co.,+1-212-983-1702 x208, or bpiacente@annemcbride.com
Web Site: http://www.annemcbride.com/
